Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Abstract

ObjectiveCisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In this study we aimed to evaluate the efficacy of these two regimens for the treatment of metastatic or recurrent cervical cancer.MethodsPatients with metastatic or recurrent cervical cancer treated with cisplatin-paclitaxel and bevacizumab or carboplatin-paclitaxel and bevacizumab were retrospectively evaluated in this study. The clinical and demographic characteristics of patients in each group were evaluated. Median overall survival, progression-free survival, and response rates between the two groups were compared.ResultsA total of 250 patients were included. Overall, the numbers of patients with recurrent disease and metastatic disease were 159 and 91, respectively. The most common histologic subtype was squamous cell carcinoma (83.2%). The median duration of follow-up was 13.6 (range 0.5–86) months. The median progression-free survival was 10.5 (95% CI 9.0 to 11.8) months in the cisplatin-paclitaxel and bevacizumab group (group 1), and 10.8 (95% CI 8.6 to 13.0) months in the carboplatin-paclitaxel and bevacizumab group (group 2) (HR 1.20; 95% CI 0.88 to 1.63; p=0.25). The median overall survival was 19.1 (95% CI 13.0 to 25.1) months in group 1 and 18.3 (95% CI 15.3 to 21.3) months in group 2 (HR 1.28; 95% CI 0.91 to 1.80; p=0.15).ConclusionsThere is no survival difference between cisplatin or carboplatin combined with paclitaxel and bevacizumab in metastatic or recurrent cervical cancer.

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer

“…In the CECILIA study [ 16 ], 57% of the patients received bevacizumab maintenance therapy for up to 53 courses. In a recent report, 18.5% of the TP plus bevacizumab group and 21.1% of the TC plus bevacizumab group received at least one or more courses of bevacizumab maintenance therapy, and the median (range) number of maintenance courses was 8 (2–24) and 9 (1–56), respectively [ 17 ]. As mentioned above, the number of bevacizumab maintenance courses currently varies and depends on the discretion of the attending physician.…”

Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study

“…Platinum–paclitaxel in combination with bevacizumab has been established as the standard treatment regimen for R/M CC, yielding an ORR of 55.8% to 64.5% and mPFS ranging from 9.2 to 10.8 months, and an mOS ranging from 16.4 to 19.1 months ( 26, 27 ). However, in patients who received platinum–paclitaxel regimens without bevacizumab, ORR ranged from 58.8% to 62.6% and mPFS ranged from 4.8 to 7.9 months in the JCOG0505 study, and mOS was 9.7 in the GOG-169 study and 13.3 months in the GOG-240 study, as previously reported ( 6, 28, 29 ).…”

Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer

“…In the literature, both cisplatin- and carboplatin-based treatments were used in neoadjuvant cervical cancer studies. It is known that objective responses are higher with cisplatin-based treatments [ 21 ]. Therefore, in the present study, cisplatin was specifically preferred for its high response rates.…”